By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rubicon Genomics said today that molecular diagnostics company Agendia will use Rubicon's whole-genome RNA amplification technology with Agendia's breast cancer diagnostic tests.

Under a clinical supply agreement, Agendia will incorporate Rubicon's TransPlex technology into the analysis of formalin fixed, paraffin-embedded patient samples for use in testing with its Symphony suite of breast cancer diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.